Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GeneDx Holdings Corp. (WGS)

GeneDx appoints Mark Gardner as President, effective June 15, 2026

Neutral Impact 3 of 5 leadership Written later

GeneDx Holdings named Mark Gardner, 60, as President effective June 15, 2026, to oversee its lab and commercial operations. He reports to CEO Katherine Stueland and joins the executive leadership team after serving as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics from September 2022 to June 2026. The filing also says Bryan Dechairo will move into a role leading product, technology and innovation initiatives.

Key points

  • Mark Gardner, 60, effective June 15, 2026; reports to CEO Katherine Stueland
  • Employment terms: base salary of $530,000, target annual bonus of 65% of base salary, and restricted stock units with a $2,000,000 grant-date value vesting over four years
  • Severance without cause or for good reason: 9 months of base salary continuation and 12 months of health coverage; enhanced terms apply within 12 months after a change in control
  • Bryan Dechairo will transition to leading product, technology and innovation initiatives

The filing

CompanyGeneDx Holdings Corp. (WGS)
Form8-K, current report
Filed with the SECJun 16, 2026, 8:39 AM ET
Accession number0001628280-26-043431

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.